Granules India: Profit & Progress
Granules India Reports 60% Profit Surge, Driven by Strategic Expansion and FDA Approvals
Anonymous
Key Points
1
Genome Valley facility's new formulations plant has cleared its first FDA pre-approval inspection, unlocking capacity for 10 billion doses of formulations.
2
Board-approved preferential issuance of 25 million warrants in December 2025, with shareholders' approval in January 2026, expanding Granules India's capital structure.
3
In Q1 FY27, the company raised about ₹365.6 crore (25% of total warrants consideration) on February 23; it issued 2.5 crore convertible warrants at ₹585 per share, convertible within 18 months, with the last conversion date in August 2027.
4
Granules India received an Establishment Inspection Report (EIR) from the US FDA for its Chantilly, Virginia facility in June 2026, signaling regulatory progress ahead of future inspections.
5
Standalone quarterly figures show standalone net profit of ₹717.46 million and standalone revenue of ₹8,018.77 million, underscoring a solid operational base alongside consolidated gains.
Granules India posted a 60% jump in net profit for Q1 FY27, earning ₹180 crore compared to ₹112.6 crore a year earlier. Revenue from operations climbed 22% to ₹1,476.8 crore, according to NDTV Profit.
The strong results sent shares in Granules India higher. The Hyderabad-based drugmaker has now surpassed the ₹50,000 million annual revenue milestone, according to ScanX Trade.
EBITDA Margins Expand as Revenue Hits New Highs
Granules India's EBITDA reached ₹339 crore in Q1 FY27, with an EBITDA margin of about 23%. That compares to a margin near 20% in the year-ago June quarter, when EBITDA stood at ₹3.39 billion. The improvement shows the company is turning higher revenue into stronger profits, according to Business Upturn.
The gross margin stood at 64.9% in the earlier quarter. Costs were higher due to US FDA remediation work and expenses tied to acquiring Senn Chemicals AG, a Swiss firm. The Senn Chemicals deal added about ₹291 million to revenue in Q1.
FDA Clearance Unlocks 10 Billion Doses of New Capacity
Granules India's Genome Valley plant passed its first US FDA pre-approval inspection. That clears the way for the company to supply new prescription products from the facility. The plant can now produce up to 10 billion doses of formulations, a major capacity boost.
The company also received an Establishment Inspection Report, or EIR, from the US FDA for its Chantilly, Virginia site in June 2026. An EIR signals the FDA is satisfied with a facility. This puts Granules in a stronger position for future product approvals in the US market.
Gagillapur Remediation on Track for Late 2026 Reinspection
Granules India is working to fix compliance issues at its Gagillapur facility. Management plans to meet with the FDA in September 2026 and aims for a reinspection in December 2026. Clearing Gagillapur would open up more capacity for regulated markets, according to ScanX Trade.
The company is also pushing into higher-value businesses like peptides and CDMO services. CDMO stands for contract development and manufacturing — where Granules makes drugs on behalf of other pharma companies. These segments carry better margins than standard generics.
Warrant Issuance Brings Fresh Capital Into the Business
Granules India's board approved a preferential issuance of 25 million warrants in December 2025. Shareholders gave their approval in January 2026. In February 2026, the company raised about ₹365.6 crore, equal to 25% of the total warrants consideration, according to Business Upturn.
The company issued 2.5 crore convertible warrants at ₹585 per share. Holders can convert them into shares within 18 months, with the last conversion date set for August 2027. The fresh capital gives Granules room to fund its expansion across APIs, finished dosages, and new high-value segments.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
74
Reach
91
Topics
A
AnonymousAuthor